The Massachusetts Biotechnology Council (MassBio) released its 2018 Industry Snapshot report, in partnership with EvaluatePharma, which shows Massachusetts biotechs accounting for nearly half of all US-based biotech IPOs (48%), up from 30% in 2016.
The report shows that 2018 has already surpassed 2017 in terms of total Massachusetts IPOs at 15, which accounts for nearly 40% of all US-based biotech IPOs (January – July 2018).
Job growth in the Massachusetts biopharma industry remains strong, with consistent 4-5% increases in the last few years, and nearly 30% growth over the last decade (28% from 2008 – 2017). Massachusetts also continues to attract a greater share of public funding, with:
To download the full report, visit here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.